Haemonetics Corp. (HAE) is Trading Higher on Unusual Volume for February 01

Equities Staff  |

Haemonetics Corp. (HAE) experienced unusually high volume on Feb. 01, as the stock gained 9.58% to a closing price of $34.67. The stock saw 786,952 shares trade hands over the course of the day on 7,368 trades. Given that the stock’s average daily volume over the last month has been 283,668 shares a day, this represents a pretty substantial spike over the norm.

Haemonetics Corp. has a P/B ratio of 2.26. It also has a P/E ratio of 64. The stock has traded between $45.43 and $29.20 over the last 52-weeks, its 50-day SMA is now $31.56, and its 200-day SMA $36.42.

Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Headquartered in Braintree, MA, Haemonetics Corp. has 3,383 employees and is currently under the leadership of CEO Ronald G. Gelbman.

For a complete fundamental analysis analysis of Haemonetics Corp., check out Equities.com’s Stock Valuation Analysis report for HAE. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Singlepoint Inc

SinglePoint Inc is a mobile technology company engaged in mobile payments, mobile giving, and mobile bidding. It operates mobile commerce and communications platform to accept mobile credit card payments.